Previously, we reported that the catalytic subunit of cAMPdependent protein kinase (PKAc) binds to the active p90 ribosomal S6 kinase 1 (RSK1) (Chaturvedi, D., Poppleton, H. M., Stringfield, T., Barbier, A., and Patel, T. B. (2006) Mol. Cell. Biol. 26, 4586 -4600). Herein, by overexpressing hemagglutinin-tagged RSK1 fragments in HeLa cells we have identified the region of RSK1 that is responsible for the interaction with PKAc. PKAc bound to the last 13 amino acids of RSK1, which overlaps the Erk1/2 docking site. This interaction between PKAc and RSK1 required the phosphorylation of Ser-732 in the C terminus of RSK1. Depending upon its phosphorylation status, RSK1 switched interactions between Erk1/2 and PKAc. In addition, a peptide corresponding to the last 13 amino acids of RSK1 with substitution of Ser-732 with Glu (peptide E), but not Ala (peptide A), decreased interactions between endogenous active RSK1 and PKAc. RSK1 attenuated the ability of cAMP to activate PKA in vitro and this modulation was abrogated by peptide E, but not by peptide A. Similarly, in intact cells, cAMPmediated phosphorylation of Bcl-xL/Bcl-2-associated death promoter on Ser-115, the PKA site, was reduced when RSK1 was activated by epidermal growth factor, and this effect was blocked by peptide E, but not by peptide A. These findings demonstrate that interactions between endogenous RSK1 and PKAc in intact cells regulate the ability of cAMP to activate PKA and identify a novel mechanism by which PKA activity is regulated by the Erk1/2 pathway.
cAMP-dependent protein kinase (PKA)2 is ubiquitously distributed in a variety of tissues and cell types and has been shown to regulate a large number of biological functions ranging from regulation of inotropic and chronotropic actions in the heart to regulation of tumorigenesis as well as modulation of long term potentiation and, therefore, memory. PKA is a heterotetramer composed of two catalytic subunits (PKAc) bound to a dimer of regulatory subunits. To date four catalytic (PKAc-␣ to PKAc-␦) and four regulatory subunit isoforms (PKARI␣, PKARI, PKARII␣, and PKARII) have been described (1). Depending upon the type of regulatory subunit (PKARI or PKARII) that the catalytic subunits are bound to, the PKA holoenzyme is referred to either as type I or type II (1). The different isoforms are differentially expressed in a cell-and tissue-specific manner (2). Besides binding to the regulatory subunits, PKAc has also been shown to bind a number of proteins. For instance, akin to the binding with regulatory subunits, binding of PKAc to the inhibitory protein of nuclear factor kappa-B (NFB), IB-␣, inhibits PKAc catalytic activity (3). Upon degradation of IB-␣ during NFB activation, PKAc is released and activated in a cAMPindependent manner (3). Likewise, the small GTP-binding protein Rab13 binds with and inhibits PKAc activity during tight junction formation (4). Thus, proteins other than the regulatory subunits of PKA can modulate the activity of the catalytic subunits of this enzyme.The p90 ribosomal S6...